| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.
|
Lancet Infect Dis
|
2009
|
6.81
|
|
2
|
Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.
|
N Engl J Med
|
2003
|
6.07
|
|
3
|
Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.
|
Clin Infect Dis
|
2014
|
5.60
|
|
4
|
Global incidence of multidrug-resistant tuberculosis.
|
J Infect Dis
|
2006
|
5.42
|
|
5
|
HIV infection and multidrug-resistant tuberculosis: the perfect storm.
|
J Infect Dis
|
2007
|
5.40
|
|
6
|
Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis.
|
Am J Respir Crit Care Med
|
2010
|
5.01
|
|
7
|
Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study.
|
Lancet
|
2005
|
3.81
|
|
8
|
Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects.
|
Antimicrob Agents Chemother
|
1998
|
3.60
|
|
9
|
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
|
J Infect Dis
|
2004
|
2.95
|
|
10
|
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
|
Int J Tuberc Lung Dis
|
2006
|
2.83
|
|
11
|
Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens.
|
J Clin Microbiol
|
2009
|
2.75
|
|
12
|
Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa.
|
PLoS One
|
2009
|
2.47
|
|
13
|
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.
|
Antimicrob Agents Chemother
|
2012
|
2.26
|
|
14
|
Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
|
Drugs
|
2002
|
2.09
|
|
15
|
Early identification of placenta praevia.
|
Br J Obstet Gynaecol
|
1990
|
2.05
|
|
16
|
Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies.
|
J Clin Pharmacol
|
2011
|
2.02
|
|
17
|
Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study.
|
Eur Respir J
|
2006
|
1.70
|
|
18
|
Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.
|
Clin Pharmacol Ther
|
2000
|
1.58
|
|
19
|
Effects of three fluoroquinolones on QT interval in healthy adults after single doses.
|
Clin Pharmacol Ther
|
2003
|
1.46
|
|
20
|
Beyond accuracy: creating a comprehensive evidence base for TB diagnostic tools.
|
Int J Tuberc Lung Dis
|
2010
|
1.40
|
|
21
|
Reaching the targets for tuberculosis control: the impact of HIV.
|
Bull World Health Organ
|
2007
|
1.12
|
|
22
|
Effects of three fluoroquinolones on QT analysis after standard treatment courses.
|
Ann Noninvasive Electrocardiol
|
2006
|
1.07
|
|
23
|
Arrhythmias associated with fluoroquinolone therapy.
|
Int J Antimicrob Agents
|
2007
|
1.05
|
|
24
|
Moxifloxacin and torsade de pointes.
|
Ann Pharmacother
|
2007
|
0.98
|
|
25
|
A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
|
Chest
|
2005
|
0.93
|
|
26
|
Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations.
|
AIDS
|
2011
|
0.91
|
|
27
|
Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event.
|
Can J Cardiol
|
2007
|
0.91
|
|
28
|
Characteristics and follow-up of postmarketing studies of conditionally authorized medicines in the EU.
|
Br J Clin Pharmacol
|
2016
|
0.91
|
|
29
|
Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis.
|
Antimicrob Agents Chemother
|
2016
|
0.89
|
|
30
|
A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis.
|
Infect Dis Ther
|
2013
|
0.86
|
|
31
|
Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan.
|
BMC Med
|
2016
|
0.85
|
|
32
|
Cardiotoxicity of fluoroquinolones.
|
J Antimicrob Chemother
|
2002
|
0.83
|
|
33
|
Moxifloxacin-induced torsades de pointes.
|
Cardiol J
|
2008
|
0.83
|
|
34
|
Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials.
|
Eur Respir Rev
|
2016
|
0.82
|
|
35
|
Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
|
Antimicrob Agents Chemother
|
2008
|
0.79
|
|
36
|
Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment.
|
Dig Liver Dis
|
2009
|
0.77
|
|
37
|
Drug-Resistant Tuberculosis: Challenges and Progress.
|
Infect Dis Clin North Am
|
2016
|
0.76
|
|
38
|
Current strategies to treat tuberculosis.
|
F1000Res
|
2016
|
0.75
|
|
39
|
Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry.
|
Antimicrob Agents Chemother
|
2015
|
0.75
|
|
40
|
Adjusting for covariates in non-inferiority studies with margins defined as risk differences.
|
Pharm Stat
|
2011
|
0.75
|
|
41
|
A classical conditioning procedure for the hearing assessment of multiply handicapped persons.
|
J Speech Hear Disord
|
1989
|
0.75
|